Welcome to our dedicated page for CRXTQ news (Ticker: CRXTQ), a resource for investors and traders seeking the latest updates and insights on CRXTQ stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRXTQ's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRXTQ's position in the market.
Tolmar Pharmaceuticals has acquired all rights to JATENZO® (testosterone undecanoate) from Clarus Therapeutics as part of a strategic move to enhance its urology and men’s health portfolio. This acquisition, approved by the U.S. Bankruptcy Court, follows a competitive bidding process. JATENZO is the first oral testosterone replacement therapy approved in over 60 years, addressing conditions linked to testosterone deficiency. Tolmar plans to leverage its successful sales force for JATENZO’s growth, expecting substantial potential and improved patient treatment options.
Clarus Therapeutics Holdings, Inc. (OTC: CRXTQ) announced the conclusion of a court-supervised auction for its product JATENZO (testosterone undecanoate capsules). The auction, held on October 14, 2022, resulted in Tolmar, Inc. being selected as the winning bidder, pending final approval from the U.S. Bankruptcy Court on October 26, 2022. The asset sale is part of Clarus’ ongoing Chapter 11 proceedings, initiated in Delaware. Stakeholders can access further details through Clarus' claims agent, Stretto.
FAQ
What is the market cap of CRXTQ (CRXTQ)?
